1. Pink Sheet
  2. >>Market Access
  3. >>Government Payers
  4. >>Medicare

Reimbursement Challenges Await COVID-19 Vaccines Given Emergency Use Authorization

 
• By Sarah Karlin-Smith

CARES Act appears to have overlooked Medicare coverage of a vaccine not granted traditional approval by US FDA. Meanwhile, other patient and provider vaccine reimbursement issues still need to be addressed by HHS and Congress to ensure widespread, affordable access to COVID-19 vaccines cleared by FDA under any pathway.  

Coronavirus_Vaccine
Uptake of COVID-19 vaccines may hinge on reimbursement policy • Source: Shutterstock

The US Congress may need to tweak legislation to ensure that Medicare beneficiaries can receive COVID-19 vaccines and providers can be reimbursed for the inoculations if vaccines are granted an emergency use authorization and not a traditional approval through US Food and Drug Administration biologics license application.

It is just one of a number of coverage and reimbursement issues that lawmakers and the Health and Human Services...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medicare

More from Government Payers

Rocky Rollout Spells Trouble for Medicare Prescription Payment Plan

 
• By Lauren Flynn Kelly

Enrollment in the new Medicare Prescription Payment Plan was lower than expected in the first year and well below CMS expectations, and invoicing data indicates members are slow to pay.

Japan Reimburses 11 New Drugs But Slashes Price Of Others By Up To 20%

 
• By Lisa Takagi

Japan's NHI program continues to give and take as 11 new drugs are granted reimbursement, while the prices of others - including three ophthalmic therapies - are cut by up to 20% under a Market Expansion Repricing scheme.

HHS Negotiating With Manufacturers On Most Favored Nation Drug Pricing

 
• By Cathy Kelly

MFN policy would would apply to all single source drugs in all insurance markets, according to HHS release. Secretary Robert F. Kennedy Jr. said the department is discussing the plan with drug sponsors.